ENTEROCOCCAL ENDOCARDITIS

被引:117
作者
MEGRAN, DW
机构
[1] UNIV CALGARY,DEPT MED,CALGARY T2N 1N4,ALBERTA,CANADA
[2] UNIV CALGARY,DEPT MICROBIOL,CALGARY T2N 1N4,ALBERTA,CANADA
[3] UNIV CALGARY,DEPT INFECT DIS,CALGARY T2N 1N4,ALBERTA,CANADA
关键词
D O I
10.1093/clinids/15.1.63
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Enterococci, most often Enterococcus faecalis, cause 5%-20% of cases of infective endocarditis (IE). Enterococcal IE is usually a disease of older men, and the most frequent source of infection is the genitourinary tract. In cases of enterococcal IE, both normal and previously damaged valves can be involved. The disease most commonly presents in a subacute fashion; clinical and laboratory features are similar to those observed with IE caused by other pathogens. Diagnosis is based on the presence of clinical criteria of IE in association with positive blood cultures. Optimal therapy entails the parenteral use of a cell wall-active agent (penicillin G, ampicillin, or vancomycin) in combination with streptomycin or gentamicin in cases caused by enterococcal strains with high-level resistance to streptomycin. A 4-week treatment course may be adequate in many cases. In patients with streptomycin-resistant strains, mitral valve disease, illness of >3 months' duration, and/or relapse after previous therapy, a 6-week treatment course should probably be administered. With standard treatment and the appropriate use of valve replacement, a cure rate of approximately 85% can be expected.
引用
收藏
页码:63 / 71
页数:9
相关论文
共 66 条
  • [1] ANTIMICROBIAL TREATMENT OF INFECTIVE ENDOCARDITIS DUE TO VIRIDANS STREPTOCOCCI, ENTEROCOCCI, AND STAPHYLOCOCCI
    BISNO, AL
    DISMUKES, WE
    DURACK, DT
    KAPLAN, EL
    KARCHMER, AW
    KAYE, D
    RAHIMTOOLA, SH
    SANDE, MA
    SANFORD, JP
    WATANAKUNAKORN, C
    WILSON, WR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (10): : 1471 - 1477
  • [2] ROLE OF IMMUNOBLOTTING IN THE DIAGNOSIS OF CULTURE NEGATIVE AND ENTEROCOCCAL ENDOCARDITIS
    BURNIE, JP
    HOLLAND, M
    MATTHEWS, RC
    LEES, W
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1987, 40 (10) : 1149 - 1158
  • [3] DAPTOMYCIN (LY146032) TREATMENT OF EXPERIMENTAL ENTEROCOCCAL ENDOCARDITIS
    BUSH, LM
    BOSCIA, JA
    KAYE, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (06) : 877 - 881
  • [4] MINIMAL CONCENTRATIONS OF AMINOGLYCOSIDE THAT CAN SYNERGIZE WITH PENICILLIN IN ENTEROCOCCAL ENDOCARDITIS
    CARRIZOSA, J
    LEVISON, ME
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 20 (03) : 405 - 409
  • [5] CARRIZOSA J, 1976, J LAB CLIN MED, V88, P132
  • [6] CARRIZOSA J, 1979, CLIN RES, V27, P341
  • [7] A CONTROLLED EVALUATION OF THE RISK OF BACTERIAL-ENDOCARDITIS IN PERSONS WITH MITRAL-VALVE PROLAPSE
    CLEMENS, JD
    HORWITZ, RI
    JAFFE, CC
    FEINSTEIN, AR
    STANTON, BF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (13) : 776 - 781
  • [8] TREATMENT OF BACTERIAL-ENDOCARDITIS WITH VANCOMYCIN
    COOK, FV
    CODDINGTON, CC
    WADLAND, WC
    FARRAR, WE
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1978, 276 (02) : 153 - 158
  • [9] MITRAL-VALVE PROLAPSE AND INFECTIVE ENDOCARDITIS
    CORRIGALL, D
    BOLEN, J
    HANCOCK, EW
    POPP, RL
    [J]. AMERICAN JOURNAL OF MEDICINE, 1977, 63 (02) : 215 - 222
  • [10] DRAKE T A, 1983, Reviews of Infectious Diseases, V5, pS345